Treatment of metastatic renal cell carcinoma.
The median survival of patients with metastatic renal cell carcinoma (mRCC) has increased from 10 months to more than 40 months since the advent of targeted therapy. Sunitinib and bevacizumab represent the first-line standards of care for patients with clear cell mRCC. Temsirolimus is the standard of care for those with poor-risk features. Additionally, exploratory analyses of the temsirolimus data indicate important benefits for those with non-clear-cell mRCC. Everolimus has proved its efficacy in second-line therapy. Sunitinib and sorafenib are also effective for non-clear-cell histological subtypes and after failure of first-line treatment. Potential survival benefits can also be derived from cytoreductive nephrectomy (CNT) in patients previously exposed to sunitinib or bevacizumab. Phase III studies are ongoing to address the importance of CNT in the targeted therapy era. Such information is crucial to ensure timely delivery of a combination of medical and surgical therapies to this patient population.
Sun
Maxine
M
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec H2X 3J4, Canada.
Lughezzani
Giovanni
G
Perrotte
Paul
P
Karakiewicz
Pierre I
PI
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy*; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007376:Interleukin-2; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; D007372:Interferons; D000077157:Sorafenib; D020123:Sirolimus
J Urol. 2007 Nov;178(5):1883-7
17868732
Urology. 2009 Oct;74(4):837-41
19616828
J Clin Oncol. 2002 Jan 1;20(1):289-96
11773181
J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63
18840822
Eur Urol. 2008 Dec;54(6):1373-8
18692304
Eur J Cancer. 1991;27 Suppl 4:S84-7
1724728
J Clin Oncol. 2009 Sep 20;27(27):4469-74
19652053
Cancer. 2007 Dec 1;110(11):2468-77
17932908
Eur Urol. 2009 Dec;56(6):959-71
19748725
J Clin Oncol. 2010 Feb 20;28(6):1061-8
20100962
J Urol. 2004 Mar;171(3):1071-6
14767273
Lancet. 2007 Dec 22;370(9605):2103-11
18156031
J Support Oncol. 2006 Apr;4(4):191-9
16669463
J Clin Oncol. 2007 Oct 10;25(29):4536-41
17876014
J Immunother. 2009 Feb-Mar;32(2):181-5
19238017
J Clin Oncol. 2008 Aug 1;26(22):3743-8
18669461
Med Oncol. 2010 Jun;27(2):373-8
19399651
Lancet Oncol. 2009 Aug;10(8):757-63
19615940
Cancer Res. 1990 Jul 15;50(14):4190-4
2364374
J Clin Oncol. 2009 Mar 20;27(9):1432-9
19224847
Can Urol Assoc J. 2008 Jun;2(3):175-82
18682778
Urology. 1995 May;45(5):758-62
7747370
Cancer. 2009 Jan 1;115(1):61-7
19051290
J Urol. 1997 Nov;158(5):1691-5
9334580
J Clin Oncol. 1995 Mar;13(3):688-96
7884429
N Engl J Med. 2007 Jan 11;356(2):185-7
17215538
J Clin Oncol. 1999 Sep;17(9):2859-67
10561363
J Surg Res. 2001 Apr;96(2):173-82
11266270
Urology. 2003 Oct;62(4):636-40
14550433
J Clin Oncol. 1999 Aug;17(8):2530-40
10561319
J Clin Oncol. 2005 Nov 1;23(31):7889-96
16204015
J Clin Oncol. 2009 Sep 20;27(27):4462-8
19652060
J Clin Oncol. 2008 Jan 1;26(1):127-31
18165647
J Urol. 2008 Jan;179(1):81-6; discussion 86
17997441
J Urol. 2009 Jul;182(1):29-34; discussion 34
19447417
Cancer. 2009 May 15;115(10 Suppl):2361-7
19402059
J Clin Oncol. 2002 May 1;20(9):2376-81
11981011
J Exp Med. 1979 Jun 1;149(6):1460-76
156241
Semin Oncol. 2009 Dec;36 Suppl 3:S26-36
19963097
Cancer J Sci Am. 2000 Feb;6 Suppl 1:S88-92
10685666
J Clin Oncol. 2010 Jan 10;28(2):207-14
19949018
Nat Rev Urol. 2009 Jul;6(7):375-83
19528960
BJU Int. 2008 Sep;102(6):692-6
18410444
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7
9457402
J Clin Oncol. 2009 Mar 10;27(8):1280-9
19171708
Value Health. 2007 Jul-Aug;10(4):285-93
17645683
Adv Immunol. 1991;50:147-235
1950796
Urology. 2009 Feb;73(2):342-6
19041122
J Urol. 1990 Sep;144(3):614-7; discussion 617-8
2201792
J Clin Oncol. 2009 Dec 1;27(34):5788-93
19884559
J Clin Oncol. 2009 Sep 1;27(25):4076-81
19636008
Ann Surg Oncol. 2004 Jan;11(1):71-7
14699037
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Clin Cancer Res. 2008 Apr 15;14(8):2431-6
18413834
Lancet. 2001 Sep 22;358(9286):966-70
11583750
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
Cancer. 2009 May 15;115(10 Suppl):2355-60
19402066
Cancer. 1995 Aug 15;76(4):687-94
8625167
J Surg Res. 2002 Jun 1;105(1):43-7
12069500
World J Urol. 2005 Jul;23(3):161-5
15711829
Clin Genitourin Cancer. 2007 Dec;5(7):427-32
18272024
Future Oncol. 2009 Aug;5(6):859-69
19663735
N Engl J Med. 1987 Apr 9;316(15):889-97
3493432
Cancer. 2009 May 15;115(10 Suppl):2262-72
19402056
Lancet. 1999 Jan 2;353(9146):14-7
10023944
J Clin Oncol. 2008 Nov 20;26(33):5422-8
18936475
Eur Urol. 2009 Jan;55(1):237-9; quiz 239
18804907
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
15674877
Drugs. 1993 Feb;45(2):177-211
7681371
JAMA. 2006 Jun 7;295(21):2516-24
16757724
J Natl Cancer Inst. 1993 Apr 21;85(8):622-32
8468720
J Clin Oncol. 1991 Apr;9(4):694-704
2066765
J Clin Oncol. 2006 Jun 1;24(16):2505-12
16636341
CA Cancer J Clin. 1993 May-Jun;43(3):177-87
8490757
J Urol. 1999 Jul;162(1):43-5
10379736
Cancer. 2006 Dec 1;107(11):2617-21
17083126
N Engl J Med. 2001 Dec 6;345(23):1655-9
11759643
Med Oncol. 2009;26(2):202-9
19229667
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Lancet. 2008 Aug 9;372(9637):449-56
18653228
Acta Oncol. 1990;29(2):155-62
2185803
J Clin Oncol. 2006 Jan 1;24(1):16-24
16330672
J Urol. 1995 Jul;154(1):32-4
7776449
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
Lancet Oncol. 2007 Nov;8(11):975-84
17959415
J Urol. 2007 Mar;177(3):855-60; discussion 860-1
17296358
J Clin Oncol. 2003 Aug 15;21(16):3127-32
12915604
Cancer. 2009 May 15;115(10 Suppl):2321-6
19402067
Urology. 2000 Jan;55(1):36-40
10654891
Science. 1976 Sep 10;193(4257):1007-8
181845
Urology. 2008 Oct;72(4):864-8
18684493
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530
J Clin Oncol. 2009 Sep 1;27(25):4068-75
19652072
Cancer. 2006 Nov 15;107(10):2375-83
17048248
Eur Urol. 2008 Apr;53(4):845-8
18053636
J Clin Oncol. 2005 Jan 1;23(1):133-41
15625368
Cancer. 2010 Jan 15;116(2):347-54
19921736
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):697s-702s
17255296
J Clin Oncol. 2009 Jul 10;27(20):3312-8
19451442
Cancer Treat Rev. 2009 Dec;35(8):733-7
19699588
J Urol. 2008 Jul;180(1):94-8
18485389
J Clin Oncol. 2009 Aug 1;27(22):3584-90
19487381
Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72
18774306